BsmI vitamin D receptor's polymorphism and bone mineral density in men and premenopausal women on long-term antiepileptic therapy

European Journal of Neurology

Volumn 18, Issue 1, 2011, Pages 93-98

  Lambrinoudaki, I ^a   Kaparos, G ^a   Armeni, E ^a   Alexandrou, A ^b   Damaskos, C ^b   Logothetis, E ^a   Creatsa, M ^a   Antoniou, A ^a   Kouskouni, E ^a   Triantafyllou, N ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bone mineral density; BsmI; Epilepsy; VDR

Indexed keywords

25 HYDROXYVITAMIN D; ANTICONVULSIVE AGENT; CALCIUM; MAGNESIUM; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D RECEPTOR;

ALLELE; ANTICONVULSANT THERAPY; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE METABOLISM; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EPILEPSY; FEMALE; GENOTYPE; HUMAN; LONG TERM CARE; LUMBAR SPINE; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NORMAL HUMAN; PHOSPHATE BLOOD LEVEL; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; ALLELES; ANTICONVULSANTS; BONE DENSITY; CALCIUM, DIETARY; CARBAMAZEPINE; CROSS-SECTIONAL STUDIES; EPILEPSY; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PIRACETAM; POLYMORPHISM, GENETIC; PREMENOPAUSE; RECEPTORS, CALCITRIOL; REGRESSION ANALYSIS; STATISTICS, NONPARAMETRIC; VALPROIC ACID;

EID: 78650106536     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2010.03103.x     Document Type: Article

References (37)

1. World Health Organization; Fact sheet No 999 (2009)
2. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004; 6: 57-75.
3. Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure 2008; 17: 181-186.
4. Samaniego EA, Sheth RD. Bone consequences of epilepsy and antiepileptic medications. Semin Pediatr Neurol 2007; 14: 196-200.
5. Stephen LJ, McLellan AR, Harrison JH, et al. Bone density and antiepileptic drugs: a case controlled study. Seizure 1999; 8: 339-342.
6. Ali II, Schuh L, Barkley GL, Gates JR. Antiepileptic drugs and reduced BMD. Epilepsy Behav 2004; 5: 296-300.
7. El-Hajj Fuleihan G, Dib L, Yamout B, Sawaya R, Mikati MA. Predictors of bone density in ambulatory patients on antiepileptic drugs. Bone 2008; 43: 149-155.
8. Petty SJ, O'Brien TJ, Wark JD. Anti-epileptic medication and bone health. Osteoporos Int 2007; 18: 129-142.
9. Tsiropoulos I, Andersen M, Nymark T, Lauritsen J, Gaist D, Hallas J. Exposure to antiepileptic drugs and the risk of hip fracture: a case-control study. Epilepsia 2008; 49: 2092-2099.
10. Valsamis HA, Arora SK, Labban B, McFarlane SI. Antiepileptic drugs and bone metabolism. Nutr Metab 2006; 3: 36.
11. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367: 284-287.
12. Eisman JA. Pharmacogenetics of the vitamin D receptor and osteoporosis. Drug Metab Dispos 2001; 29: 505-512.
13. Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009; 50: 1-23.
14. Szoeke CE, Newton M, Wood JM, et al. Update on pharmacogenetics in epilepsy: a brief review. Lancet Neurol 2006; 5: 189-196.
15. Goldstein DB, Need AC, Singh R, Sisodiya SM. Potential genetic causes of heterogeneity of treatment effects. Am J Med 2007; 120: 21-25.
16. Hadjidakis D, Kokkinakis E, Giannopoulos G, Merakos G, Raptis SA. Bone mineral density of vertebrae, proximal femur and os calcis in normal Greek subjects as assessed by dual-energy X-ray absorptiometry: comparison with other populations. Eur J Clin Invest 1997; 27: 219-227.
17. Haussler MR, Haussler CA, Jurutka PW, et al. The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol 1997; 154: 57-73.
18. Zmuda JM, Cauley JA, Ferrell RE. Molecular epidemiology of vitamin D receptor gene variants. Epidemiol Rev 2000; 22: 203-217.
19. Jurutka PW, Whitfield GK, Hsieh J-C, Thompson PD, Haussler CA, Haussler MR. Molecular nature of the vitamin D receptor and its role in regulation of gene expression. Rev Endocr Metab Disord 2001; 2: 203-216.
20. Thakkinstian A, D'Este C, Eisman J, Nguyen T, Attia J. Meta-analysis of molecular association studies: vitamin D receptor gene polymorphisms and BMD as a case study. J Bone Miner Res 2004; 19: 419-428.
21. Fleet JC, Harris SS, Wood RJ, Dawson-Hughes B. The BsmI vitamin D receptor restriction fragment length polymorphism (BB) predicts low bone density in premenopausal black and white women. J Bone Miner Res 1995; 10: 985-990.
22. Garnero P, Munoz F, Borel O, Sornay-Rendu E, Delmas PD. Vitamin D receptor gene polymorphisms are associated with the risk of fractures in postmenopausal women, independently of BMD. J Clin Endocrinol Metab 2005; 90: 4829-4835.
23. Chatzipapas C, Boikos S, Drosos GI, et al. Polymorphisms of the vitamin D receptor gene and stress fractures. Horm Metab Res 2009; 41: 635-640.
24. Feskanich D, Hunter DJ, Willett WC, et al. Vitamin D receptor genotype and the risk of bone fractures in women. Epidemiology 1998; 9: 535-553.
25. Lorentzon M, Lorentzon R, Nordström P. Vitamin D receptor gene polymorphism is related to bone density, circulating osteocalcin and parathyroid hormone in healthy adolescent girls. J Bone Miner Metab 2001; 19: 302-307.
26. Macdonald HM, McGuigan FE, Stewart A, et al. Large-scale population-based study shows no evidence of association between common polymorphism of the VDR gene and BMD in British women. J Bone Miner Res 2006; 21: 151-162.
27. Howard G, Nguyen T, Morrison N, et al. Genetic influences on bone density: physiological correlates of vitamin D receptor gene alleles in premenopausal women. J Clin Endocrinol Metab 1995; 80: 2800-2805.
28. Fernandez E, Fibla J, Betriu A, Piulats JM, Almirall J, Montoliu J. Association between vitamin D receptor gene polymorphism and relative hypoparathyroidism in patients with chronic renal failure. J Am Soc Nephrol 1997; 8: 1546-1552.
29. Ferrara M, Matarese SM, Francese M, et al. Effect of VDR polymorphisms on growth and bone mineral density in homozygous beta thalassaemia. Br J Haematol 2002; 117: 436-440.
30. Obermayer-Pietsch BM, Frühauf GE, Chararas K, et al. Association of the vitamin D receptor genotype BB with low bone density in hyperthyroidism. J Bone Miner Res 2000; 15: 1950-1955.
31. Torres A, Machado M, Concepción MT, et al. Influence of vitamin D receptor genotype on bone mass changes after renal transplantation. Kidney Int 1996; 50: 1726-1733.
32. Pack AM, Morrell MJ. Epilepsy and bone health in adults. Epilepsy Behav 2004; 5: 24-29.
33. Boluk A, Guzelipek M, Savli H, Temel I, Ozisik HI, Kaygusuz A. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res 2004; 50: 93-97.
34. Ensrud KE, Walczak TS, Blackwell TL, et al. Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology 2008; 71: 723-730.
35. Tsukahara H, Kimura K, Todoroki Y, et al. Bone mineral status in ambulatory pediatric patients on long-term anti-epileptic drug therapy. Pediatr Int 2002; 44: 247-253.
36. Christakos S, Raval-Pandya M, Wernyj RP, Yang W. Genomic mechanisms involved in the pleiotropic actions of 1, 25- dihydroxyvitamin D3. Biochem J 1996; 316: 361-371.
37. Honkakoski P, Negishi M. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J 2000; 347: 321-337.